PYC Therapeutics Limited has appointed Douglas (Doug) Huey as Chief Executive Officer (CEO) and Board Director effective 11 February 2020. Doug will be based in the USA and will establish PYC's US-based office in Boston, representing a major step for the Company as it progresses towards clinical drug development. As global CEO, Doug will build a team in Boston that works with PYC's Perth-based operations, while being closer to US-based investors, partners, and regulators.

Rohan Hockings will transition the CEO role to Doug and will remain with the Company as both a Board Director and as Chief Strategy Officer, where he will continue to shape the Company's focus and external collaborations.